Specifically, we found that high level of JARID1B is tightly associated with chemotherapy resistance after adjusted with other factors that correlate to chemotherapy resistance such as residual tumor size and chemotherapy regimen via multivariate logistic regression analysis (OR 36.81, 95 % CI 4.84–280.11, P < 0.001), indicating JARID1B is an independent factor for chemotherapy resistance in EOC. The gene discussed is KDM5B; the disease is neoplasm.